Statistics from Altmetric.com
Is lamotrigine an effective and safe augmentation treatment in schizophrenic patients who are resistant to clozapine?
Total symptom score, positive and negative subscales of the Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS), and adverse events.
Systematic review with meta-analysis.
The Cochrane Schizophrenia Group’s PsiTri database was searched without year or language limits. This database includes trials identified from regular searches of MEDLINE, EMBASE, CENTRAL, CINAHL, PsycINFO and BIOSIS Inside as well as conference proceedings and relevant journals. Clinical trials registers, relevant journals and reference lists of included studies were also searched and authors were contacted for further information.
Study selection and analysis:
Randomised controlled trials in people with schizophrenia receiving clozapine, which compared lamotrigine with placebo, were included. It was not reported how many reviewers selected the studies. Two reviewers independently extracted the data and assessed study quality based on the level of allocation concealment; studies at high risk of bias were excluded from the meta-analysis. The mean …
Sources of funding Annual EVO Financing (special government subsidies) from Niuvanniemi Hospital.
Competing interests: DG has received research funding and honoraria for serving on an advisory board from GlaxoSmithKline, the manufacturer of lamotrigine.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.